Qualigen Therapeutics Inc (QLGN) — Capital Reinvestment Ratio

Latest as of September 2023: 0.27x

Qualigen Therapeutics Inc (QLGN) has a Capital Reinvestment Ratio of 0.27x as of September 2023, meaning it reinvests 0% of its operating cash flow ($929.74K) in capital expenditures ($246.42K). See Qualigen Therapeutics Inc net asset quality index to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.27x
Capex / Operating Cash Flow

Operating Cash Flow

$929.74K
USD

Capital Expenditures

$246.42K
USD

Data as of

Sep 2023
Most recent filing

Qualigen Therapeutics Inc Capital Reinvestment Ratio (2019–2019)

This chart tracks Qualigen Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. Check QLGN cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Qualigen Therapeutics Inc (2019–2019)

Year-by-year Capital Reinvestment Ratio for Qualigen Therapeutics Inc from 2019 to 2019. For live market cap and broader valuation context, see Qualigen Therapeutics Inc market capitalisation.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2019 3.39x $57.33K $194.48K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow